HGSI promises many, many antibodies

On the back of Wednesday's deal with Cambridge Antibody Technology (LSE:CAT), Human Genome Sciences is moving toward an exponential outpouring of human antibodies, according to Chairman and CEO William Haseltine.

The combination of CAT's phage display technology and HGSI's antigens will make possible the development of "expression proteomics," based on a high-throughput genomics-based approach to human antibodies, he said. ...